These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

Source Motley_fool

Key Points

  • AbbVie, Gilead, and Becton, Dickinson have all beaten the S&P 500 this year.

  • Two are Dividend Kings, and Gilead has raised its payout by 74.5% over the past decade.

  • 10 stocks we like better than AbbVie ›

Artificial intelligence (AI) stocks continue dominating headlines on Wall Street. That probably won't change anytime soon. But investors shouldn't be so distracted by the AI revolution that they forget there are attractive investment opportunities elsewhere. Consider the following three healthcare dividend stocks: AbbVie (NYSE:ABBV), Gilead Sciences (NASDAQ:GILD), and Becton, Dickinson (NYSE:BDX). All three have crushed broader equities this year, and they still have plenty of upside ahead for investors willing to stay the course. Read on to find out more.

Scientist using a pipette to prepare samples at a laboratory bench

Image source: Getty Images.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

1. AbbVie

AbbVie did not perform well in the first four months of the year, but it has recovered, and its shares are now up 29% to date, while the S&P 500 has gained 10%. There are several reasons behind the drugmaker's strong performance, perhaps none more important than its two biggest growth drivers, Skyrizi and Rinvoq. These two immunology medicines are performing better than management -- and Wall Street -- expected.

Considering they won't lose patent protection anytime soon, and AbbVie will face no other major loss of patent exclusivity through the end of this decade, we can expect consistent revenue and earnings growth over the medium term. Still, Skyrizi and Rinvoq will eventually face patent cliffs, with the former perhaps starting around 2033. The good news is AbbVie is preparing for that.

AbbVie has strengthened its immunology pipeline through an acquisition and is looking to enter the fast-growing weight-loss market. Further, legacy products, especially its Botox franchise, should perform well over the long term. AbbVie's excellent underlying business will help support its dividend program.

The company is a Dividend King, one of the corporations that have increased their payouts for at least 50 consecutive years. It would take something catastrophic for AbbVie to suspend or decrease its dividends. Until then, expect regular dividend increases alongside solid returns from the company.

2. Gilead Sciences

Gilead Sciences' shares have gained 37% this year on the back of improving financial results and solid clinical and regulatory progress. The biotech leader still makes most of its money from its HIV franchise, with medicines like Biktarvy doing much of the heavy lifting. And even though Veklury, a coronavirus medicine, is harming top-line growth, the company has performed well.

Gilead Sciences' third-quarter product sales grew 13% year over year -- its fastest growth rate in this category in over a decade -- to $8.29 billion. Total revenue was $8.30 billion, up almost 7% compared to the year-ago period. Product sales excluding Veklury jumped 16% year over year.

So, as Veklury continues to fade into insignificance, Gilead should record stronger top-line growth, especially as it has strengthened its HIV and oncology businesses this year with new approvals and important label expansions. The biotech giant's outlook appears stronger than it has been in a while, and its dividend program remains attractive. Gilead Sciences offers a forward yield of 2%, and it has increased its payouts by 74.5% over the past 10 years.

3. Becton, Dickinson

Becton, Dickinson, a medical technology company, is finally bouncing back after several challenging years. Shares are up 43% to date. One reason for the company's strong performance is its excellent financial results. In the fourth quarter of its fiscal year 2026, which ended Sept. 30, Becton, Dickinson's revenue increased by 5.4% year over year to $5.3 billion. Adjusted earnings per share rose 27.3% year over year to $4.15.

That's a strong performance for the healthcare giant. Another factor behind Becton, Dickinson's results is that it is benefiting from the soaring demand for GLP-1 products and should continue to do so over the medium term.

Growing demand for injectable diabetes and weight-loss medicines is driving significant increases in sales of prefillable syringes and self-injection devices for GLP-1 drugs. With the GLP-1 market projected to expand rapidly over the next five to 10 years, this tailwind may be just starting for Becton, Dickinson.

Meanwhile, the company's underlying business outside of that is resilient and highly predictable. Becton, Dickinson generates most of its revenue from recurring consumables. Finally, Becton, Dickinson is an excellent dividend stock. It is also a Dividend King with a streak of 55 consecutive payout increases.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Gilead Sciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Fed Rate Decision This Week: Will the US Dollar Strengthen and Gold Prices Fall? (26 October 2026)Fed decision, US inflation and Middle East tensions take centre stage. Explore the US dollar, gold and AUD/USD outlook for Australian traders.
Author  Mitrade Team
Oct 26, Mon
Fed decision, US inflation and Middle East tensions take centre stage. Explore the US dollar, gold and AUD/USD outlook for Australian traders.
placeholder
Bitcoin Price Outlook For November 2026: One Price Level Remains CriticalBitcoin price enters November defending $76,000, the average cost basis of short-term holders. The level was held after the Binance hack pushed BTC to a six-week low of $76,275.The shock from Binance
Author  Beincrypto
Nov 03, Tue
Bitcoin price enters November defending $76,000, the average cost basis of short-term holders. The level was held after the Binance hack pushed BTC to a six-week low of $76,275.The shock from Binance
placeholder
Market News Today Australia: Gold Falls Below $3,900, WTI Oil Jumps as Nvidia Slides Gold plunges below US$3,900, WTI oil jumps over 2%, and Nvidia falls after its CEO exits. Explore the latest market news and outlook for Australian traders.
Author  Mitrade Team
Nov 13, Fri
Gold plunges below US$3,900, WTI oil jumps over 2%, and Nvidia falls after its CEO exits. Explore the latest market news and outlook for Australian traders.
placeholder
3 Key Events in the Coming Week That Could Move AI Stocks and CryptoNvidia earnings, Fed minutes, and Anthropic’s IPO all land between Tuesday and Thursday in the coming week. Each will test an AI selloff that has also spilled into crypto.Rates add a second layer of r
Author  Beincrypto
21 hours ago
Nvidia earnings, Fed minutes, and Anthropic’s IPO all land between Tuesday and Thursday in the coming week. Each will test an AI selloff that has also spilled into crypto.Rates add a second layer of r
placeholder
Weekly Market Wrap: Nvidia Lost Its CEO, but AI Stocks Found New LeadersNvidia’s leadership shock has put the AI trade in focus, but other technology stocks are emerging as new market leaders. Explore this week’s key market moves, shifting investor sentiment and what Australian traders should watch next.
Author  Mark Garro
21 hours ago
Nvidia’s leadership shock has put the AI trade in focus, but other technology stocks are emerging as new market leaders. Explore this week’s key market moves, shifting investor sentiment and what Australian traders should watch next.
goTop
quote